Medication Non-Adherence in Rheumatology, Oncology and Cardiology: A Review of the Literature of Risk Factors and Potential Interventions
Pace Clinical
(updated: )
23-04-2026 09:05
A very interesting read, shared by our BEAMER colleagues at Pfizer. It identifies not only risk factors for adherence in three disease areas, but also the potentially most effective interventions to improve adherence. The conclusions of this 2022 publication are fully in line with our rationale in 2017 to start developing our Adherence Risk Management (ARM) services for clinical studies.
